Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Dec 28, 2016 (10 years ago)

Flucanozole Tablets (Fluconazole)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Dissolution Specifications; 18 month stability time point

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

Flucanozole Tablets, USP, 200 mg, a) 30 count (NDC 55111-146-30) and b) 100 count (NDC 55111-146-01) bottles, Rx Only, Mfd. by: Dr. Reddy's Laboratories, Bachupally 500 090 India

Affected NDCs 55111-0146-01 55111-0146-30

Compare with the code on your package — it is the most precise check available.

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Fluconazole
NDC 55111-0146
200 mg/1 Tablet
Oral
Dr. Reddy's Laboratories Limited Rx
Recalling firm
Dr. Reddy's Laboratories, Inc.
NDC code
55111-146-30
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0452-2017 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by Dr. Reddy's Laboratories, Inc.

All 2016 recalls
Class III · Low risk

Varenicline Tablets

Sub potent drug: during the 9-month stability test conducted, the assay value for the affected lot was below specification limit.

Ongoing Wrong potency / content Dr. Reddy's Laboratories, Inc. NDC 43598-908-56 D-0219-2026
Class II · Moderate risk

Omeprazole Delayed-release Capsules

Presence of foreign tablets/capsules: presence of foreign Divalproex Sodium Extended-Release 250mg tablet in a bottle of omeprazole capsules.

Ongoing Particulate / foreign matter Dr. Reddy's Laboratories, Inc. NDC 82009-022-10 D-0525-2025
Class I · High risk

Levetiracetam 0.75% in Sodium Chloride Injection 1

LABELING: LABEL MIX-UP: The infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL.

Ongoing Labeling / mix-up Dr. Reddy's Laboratories, Inc. NDC 43598-636-52 D-0365-2025

Other dissolution failure recalls from 2016

All dissolution failure recalls
Class II · Moderate risk

Flucanozole Tablets

Failed Dissolution Specifications; 18 month stability time point

Terminated Dissolution failure Dr. Reddy's Laboratories, Inc. NDC 55111-145-12 D-0451-2017
Class II · Moderate risk

Flucanozole Tablets

Failed Dissolution Specifications; 18 month stability time point

Terminated Dissolution failure Dr. Reddy's Laboratories, Inc. NDC 55111-144-30 D-0450-2017
Class II · Moderate risk

Flucanozole Tablets

Failed Dissolution Specifications; 18 month stability time point

Terminated Dissolution failure Dr. Reddy's Laboratories, Inc. NDC 55111-143-30 D-0449-2017
Class II · Moderate risk

Nadolol Tablets

Failed dissolution specification: recalled due to an out of specification dissolution result of 40% (Specification: NLT 80%)

Terminated Dissolution failure Sandoz Incorporated NDC 0781-1182-10 D-0236-2017